World Journal of Pharmaceutical and Life Sciences

www.wjpls.org

Impact Factor: 8.21 Coden USA: WJPLA7

ROLE OF *MOMORDICA CHARANTIA* IN GLYCEMIC CONTROL AND METABOLIC REGULATION

Shailendra Bahadur Singh*, Jitendra Kumar Malik, Gyan Singh, Vivek Gupta, Yogesh Bhardwaj

Research Scholar, Faculty of Pharmacy, PK University, Thanra - 473665, Madhya Pradesh, India.

***Corresponding Author: Shailendra Bahadur Singh**

Research Scholar, Faculty of Pharmacy, PK University, Thanra - 473665, Madhya Pradesh, India.

DOI: https://doi.org/10.5281/zenodo.19886216

How to cite this Article: Shailendra Bahadur Singh*, Jitendra Kumar Malik, Gyan Singh, Vivek Gupta, Yogesh Bhardwaj. (2026). Role of Momordica Charantia In Glycemic Control and Metabolic Regulation. World Journal of Pharmaceutical and Life Sciences, 12(5), 122–131.

Article Received on 02/04/2026 **Article Revised on 22/04/2026** **Article Published on 01/05/2026**

ABSTRACT

Momordica charantia (bitter melon), a nutraceutical-rich medicinal plant of the Cucurbitaceae family, is gaining global attention as a multi-target therapeutic candidate for diabetes and metabolic disorders. This review presents a concept-driven and mechanistically enriched synthesis of its phytochemical architecture, molecular mechanisms of glycemic regulation, and systemic metabolic effects. The plant contains diverse bioactive constituents such as charantin, polypeptide-p, vicine, cucurbitane-type triterpenoids, flavonoids, and phenolic compounds, which act through synergistic and network-based interactions. Experimental and clinical evidence suggests that Momordica charantia modulates glucose homeostasis via integrated pathways, including stimulation of insulin secretion, enhancement of insulin sensitivity, activation of AMP-activated protein kinase, facilitation of GLUT4-mediated glucose uptake, and inhibition of carbohydrate-digesting enzymes. Beyond glycemic control, it demonstrates significant potential in metabolic reprogramming by improving lipid profiles, suppressing oxidative stress, and attenuating chronic inflammation. Notably, its pleiotropic pharmacological profile aligns with systems pharmacology, supporting its relevance in precision medicine. However, translational challenges persist, including variability in phytochemical composition, lack of standardized formulations, insufficient pharmacokinetic data, and limited large-scale clinical validation. Addressing these gaps through advanced analytical technologies, improved bioavailability strategies, and well-designed clinical studies is essential. Overall, Momordica charantia represents a promising, innovative, and holistic plant-based intervention for comprehensive metabolic regulation and future therapeutic development. Its integration into functional foods, nutraceutical formulations, and combination therapies may further enhance therapeutic outcomes while minimizing adverse effects and improving patient compliance in long-term metabolic disease management strategies worldwide with significant clinical implications. Future interdisciplinary research integrating omics technologies and digital health tools will accelerate translational success.

KEYWORDS: *Momordica charantia*, Bitter melon, Antidiabetic, Glycemic control, Metabolic regulation.

1. INTRODUCTION

Diabetes mellitus is a chronic metabolic disease that is typified by sustained hyperglycemia, which is caused by abnormalities in insulin secretion, or insulin action or both. It is a significant worldwide health issue and is strongly linked with such complications as cardiovascular diseases, neuropathy, nephropathy, and retinopathy.[1] In coexistence with diabetes, metabolic diseases such as obesity, dyslipidemia, and metabolic syndrome have been increasing at a very high rate because of sedentary life, unhealthy eating habits and genetic inclinations. These comorbidities are major causes of morbidity and mortality in all parts of the world, and thus the dire need to find an effective and sustainable treatment plan.[2]

Even though modern pharmacotherapy has made significant progress, the treatment of diabetes and metabolic disorders is still difficult. Among the most common antidiabetic medications that are commonly linked to some limitations are insulin, sulfonylureas, and biguanides that are characterized by adverse effects, high

cost, hypoglycemia, and decreased long term effects. In addition, these treatments are more oriented towards glycemic control, and might not be sufficient in the context of multi factorial character of metabolic dysfunction [3]

In this regard, herbal medicines have become a subject of growing focus as complementary and alternative medicine. Multi-target mechanisms associated with medicinal plants include antioxidant, anti-inflammatory and insulin-sensitizing effects due to the available bioactive phytoconstituents and are therefore useful in whole metabolic management.[4] Momordica charantia (bitter melon) is one of them that have become a promising plant with a well-documented use in the management of diabetes. It is well known to have hypoglycemic, hypolipidemic and antioxidant effects which can be proved by experimental research as well as clinical research. Thus, its impact on glycemic regulation and metabolism is of high scientific and clinical interest.[5]

2. Literature Search Methodology

The systematic and complete literature search was done to gather appropriate scientific information regarding the role of Momordica charantia in regulation of glucose levels in the body and metabolism. Several electronic databases, such as PubMed, ScienceDirect and Google Scholar were also searched widely in order to cover a wide range of literature available. The search strategy was formulated to encompass original research articles and review papers in English.[6]

Relevant studies were accessed using appropriate keywords and their combinations such as: Momordica charantia, bitter melon, antidiabetic activity, glycemic control and metabolic regulation. It used the AND and OR operators to narrow down the search results and enhance relevancy. Also, reference lists of the chosen articles were also screened manually to find any other relevant studies that could have been overlooked during the search process in databases.[7]

The inclusion criteria were set to make sure that scientifically valid and relevant studies are selected. These comprised in vitro research on cellular mechanism, in vivo experimental researches on animal models and clinical researches on the effectiveness of Momordica charantia on human beings. Phytochemical analysis and pharmacological and metabolic studies were also taken into consideration.[8]

The exclusion criteria included studies that lacked enough methodological information, were not experimentally validated, had redundant information, or had a weak scientific design. Articles that were not directly related to glycemic control and metabolic regulation were also eliminated. The literature gathered was critically reviewed and systematically compiled to give a coherent and evidence-based review.[9]

3. Botanical Description and Ethnomedicinal Uses

Bitter melon or bitter gourd or *Momordica charantia* is a climbing vine (monoecious, herbaceous) of family Cucurbitaceae. Slender, angular, and extremely branched stems characterize the plant and are helped to climb by simple and coiled tendrils. It has alternate, simple and deeply palmately lobed leaves, which typically have 5-7 lobes, and thus appear unique. The surface of the leaf is somewhat rough and the venation is eminent. The plant has small, single-flowered, yellow, unisexual flowers, male and female flowers being produced on different parts of the same plant. The most salient feature is the fruit which is oblong to spindle-shaped, long, and warty with irregular protuberances on it. It is green and changes to yellow to orange when it is ripe and then splits open revealing bright red arils that protect flattened seeds.[10]

Momordica charantia has a wide spread geographically and is found in both tropical and subtropical areas of the world. It is widely grown in India, China, Indonesia, Thailand and some sections of Africa and South America. The plant grows well in warm and humid climatic conditions and likes well-drain soils and plenty of sunlight. Because of its flexibility and economic usefulness, it is usually cultivated in farmlands, backyard gardens and in rural regions.[11]

Momordica charantia has been in use in traditional systems of medicine since ancient times, notably Ayurveda and traditional Chinese medicine ethnomedically. It is used in therapy with different parts of the plant such as the fruits, leaves, seeds and roots. Its antidiabetic effect is the most notable, which was traditionally used to lower the level of blood glucose. It is also used to treat digestive disorders, obesity, microbial infections, inflammation, and liver-related disorders. It has extensive traditional usage, which has played a major role in the increase in scientific attention to its pharmacological potential and therapeutic use in metabolic disorders.[12]



Figure 1: Botanical morphology of Momordica charantia.[13]

Table 1: Taxonomical Classification and Ethnomedicinal Uses of *Momordica charantia*.[14]

Parameter	Description
Kingdom	Plantae
Division	Magnoliophyta
Class	Magnoliopsida
Order	Cucurbitales
Family	Cucurbitaceae
Genus	*Momordica*
Species	*Momordica charantia*
Common names	Bitter melon, Bitter gourd, Karela
Plant type	Climbing herbaceous vine
Parts used	Fruit, leaves, seeds, roots
Habitat	Tropical and subtropical regions
Distribution	Widely cultivated in India, China, Southeast Asia, Africa
Traditional use (antidiabetic)	Used to lower blood glucose levels
Traditional use (digestive aid)	Improves digestion and treats gastrointestinal disorders
Traditional use (metabolic disorders)	Used in obesity, dyslipidemia, and inflammation management

4. Phytochemical Profile

Momordica charantia is also considered to have a high therapeutic potential mainly due to its phytochemical composition, which is abundant and diverse. Phytochemical studies have shown that there are numerous classes of bioactive secondary metabolites, and they are collectively involved in its antidiabetic and metabolic regulatory activity. The qualitative and quantitative make-up of these constituents can differ by part of the plant, the geographical source, and mode of extraction.[15]

4.1 Preliminary Phytochemical Screening

Initial phytochemical screening of extracts of Momordica charantia has consistently shown that a number of key classes of compounds are present. They are alkaloids, flavonoids, saponins, glycosides, tannins and terpenoids. Their identification is usually done by the use of standard qualitative tests like the Dragendorff test of alkaloids, Shinoda test of flavonoids, foam test of saponins and Keller Killani test of glycosides. The most prominent ones include flavonoids and phenolics (which have strong antioxidant potential) and saponins and glycosides (related to hypoglycemic effects). These phytoconstituents facilitate the use of the plant in the management of diabetes and other metabolic disorders, which are associated with it.[16]

4.2 Major Bioactive Constituents

There are a number of important bioactive compounds that have been determined to have the pharmacological effects of Momordica charantia. One of the most well-known steroidal saponins is Charantin that has a strong hypoglycemic effect. The Polypeptide-p is an insulin-like peptide, which imitates the activity of insulin and is essential in the reduction of glucose levels in blood. Vicine is a pyrimidine glycoside that helps in lowering glucose. Phenolic compounds and flavonoids, further, have a potent antioxidant capacity, and they inhibit oxidative stress related to diabetes. These substances

have synergistic effects to control glucose metabolism and enhance the overall metabolism.[17]

4.3 Analytical Techniques

The identification, characterization and quantification of the phytochemicals found in Momordica charantia are done using advanced methods of analysis. The charantin and phenolics are some of the essential bioactive compounds that are separated and quantified using high-performance liquid chromatography (HPLC). Gas chromatography-mass spectrometry (GC-MS) is applied to the identification of volatile and semi-volatile compounds, which gives a detailed chemical profiling. Thin-layer chromatography (TLC) is a basic and fast screening and fingerprinting technique of plant extracts. These methods of analysis guarantee proper characterization and standardization of phytochemical constituents that are necessary in therapeutic use.[18]

Table 2: Major Phytochemicals Reported in *Momordica charantia*.[19]

Plant Part	Compound	Class	Pharmacological Activity
Fruit	Charantin	Steroidal saponin	Hypoglycemic activity
Seeds	Polypeptide-p	Peptide	Insulin-like activity
Seeds	Vicine	Glycoside	Glucose-lowering effect
Fruit	Momordicin	Triterpenoid	Antidiabetic, anti-inflammatory
Leaves	Quercetin	Flavonoid	Antioxidant activity
Leaves	Kaempferol	Flavonoid	Anti-inflammatory, antioxidant
Fruit	Gallic acid	Phenolic compound	Antioxidant activity
Leaves	Catechin	Flavonoid	Free radical scavenging
Whole plant	Alkaloids	Alkaloids	Metabolic regulation
Fruit	Saponins	Saponins	Hypoglycemic effect
Leaves	Tannins	Polyphenols	Astringent, antioxidant
Fruit	Cucurbitacins	Triterpenoids	Antidiabetic, anticancer
Seeds	Sterols (β-sitosterol)	Phytosterol	Lipid-lowering activity
Leaves	Phenolic acids	Phenolics	Antioxidant activity
Whole plant	Terpenoids	Terpenoids	Anti-inflammatory, metabolic regulation

5. Glycemic Control Activity

Momordica charantia has been extensively studied in terms of its antidiabetic potential using in vitro, in vivo and clinical studies. The results of these studies indicate that it can control glucose homeostasis by several mechanisms and this proves its application in the traditional management of diabetes.[20]

5.1 In Vitro Studies

In vitro research offers valuable information on the cellular and molecular pathways of the hypoglycemic effect of Momordica charantia. Plant extracts have been found to increase the uptake of glucose in other cell types, including skeletal muscle and adipocyte cells, mainly by increasing the levels of glucose transporter proteins like GLUT4. This helps to enhance the use of glucose by the cells and therefore the level of glucose in the blood is decreased.[21]

Also, Momordica charantia has been shown to have an inhibitory effect on some of the most important carbohydrate-digesting enzymes such as α-glucosidase and α-amylase. The plant inhibits the activity of these enzymes, which in turn slows down the breakdown of complex carbohydrates to glucose, resulting in less postprandial hyperglycemia. Such results emphasize its possible use in regulating the blood glucose levels at cellular and digestive levels.[22]

5.2 In Vivo Studies

Glucose-lowering effects of Momordica charantia in vivo studies have been consistently demonstrated in diabetic animal models. The application of plant extract has led to large decreases in the level of fasting blood glucose, as well as increase in glucose tolerance. These effects are usually followed by an increase in the secretion of insulin and functional ability of the pancreatic 8-cells.[23]

Moreover, it has been reported that insulin sensitivity and reduction of insulin resistance have been improved through the use of it, which are vital to type 2 diabetes management. The plant has also demonstrated positive impacts on lipid profiles and oxidative stress markers suggesting its expanded activity in metabolic control.[24]

5.3 Clinical Studies

The antidiabetic effects of *Momordica charantia* have been given supportive evidence by clinical investigations on human subjects. Its extracts, juice or products formulations have been linked to a decrease in fasting blood glucose levels as well as postprandial glucose levels.[25]

In addition, there have been a few studies that have indicated an improvement in glycated hemoglobin (HbA1c), a measure of improved long-term glycemic control. Nonetheless, it has been found to be variable in clinical outcomes as a result of variance in dosage, formulation, and study design. Nonetheless, the general

results indicate that *Momordica charantia* has potential as an adjunctive treatment option in the treatment of diabetes.[26]

Table 3: Summary of Antidiabetic Studies of *Momordica charantia*.[27]

Study Type	Model/System	Extract/Formulation	Key Findings
In vitro	L6 muscle cells	Methanolic extract	Increased glucose uptake
In vitro	3T3-L1 adipocytes	Ethanolic extract	Enhanced GLUT4 translocation
In vitro	Enzyme assay	Aqueous extract	α-glucosidase inhibition
In vitro	Enzyme assay	Methanolic extract	α-amylase inhibition
In vitro	HepG2 cells	Fruit extract	Improved glucose metabolism
In vivo	Streptozotocin-induced rats	Aqueous extract	Reduced fasting blood glucose
In vivo	Alloxan-induced rats	Ethanolic extract	Improved insulin secretion
In vivo	Diabetic mice	Fruit juice	Enhanced glucose tolerance
In vivo	High-fat diet rats	Seed extract	Reduced insulin resistance
In vivo	Diabetic rats	Leaf extract	Improved lipid profile
In vivo	Experimental rats	Charantin isolate	Significant hypoglycemic effect
Clinical	Type 2 diabetic patients	Fresh fruit juice	Reduced fasting blood glucose
Clinical	Human subjects	Capsule formulation	Improved HbA1c levels
Clinical	Diabetic patients	Powdered extract	Better glycemic control
Clinical	Controlled trial	Standardized extract	Moderate antidiabetic efficacy

6. Mechanisms of Glycemic Control and Metabolic Regulation

The effect of *Momordica charantia* in diabetes and metabolic disorders is therapeutic since the plant is able to modify the activation of various biochemical pathways at the same time. Its bioactive constituents, in contrast to single-target synthetic drugs, operate in a network of different mechanisms, which jointly govern glucose homeostasis and metabolic balance. It is a multifunctional metabolic modulator that is facilitated by pancreatic, hepatic, intestinal, and peripheral tissue actions.[28]

6.1 Enhancement of Insulin Secretion

Stimulation of pancreatic β-cell insulin secretion is one of the major mechanisms of action of Momordica charantia. Other compounds are known to either mimic insulin or increase endogenous insulin release e.g. polypeptide-p and charantin. This is especially useful in situations where there is a compromise in β-cell functioning. Moreover, certain studies indicate that the plant can guard against the effects of oxidative stress on the β-cells and, therefore, maintain their functional integrity and sustain insulin production.[29]

6.2 Improvement of Insulin Receptor Sensitivity

Momordica charantia enhances insulin sensitivity by increasing the sensitivity of insulin receptors of peripheral tissues including skeletal muscle and fat tissues. This causes more glucose transporter proteins to be translocated to the cell membrane especially GLUT4 hence efficiently taking up glucose. The plant is useful in lowering the resistance to insulin and thus normalises the glucose usage and eliminates the chronic hyperglycemia that is a significant cause of metabolic dysfunction.[30]

6.3 Activation of AMP-Activated Protein Kinase (AMPK)

AMP-activated protein kinase (AMPK) is an important process mediating the metabolic response of Momordica charantia. AMPK is a sensor of cellular energy and control of essential metabolic functions. Its stimulation increases glucose uptake, fatty acid oxidation, and decreases hepatic gluconeogenesis. This leads to better energy homeostasis, lower blood glucose and increased metabolic efficiency. The AMPK pathway can also be used to decrease lipid deposition and enhance insulin sensitivity.[31]

6.4 Inhibition of Intestinal Glucose Absorption

The other significant mechanism is the suppression of the digestion of carbohydrates in the intestine and glucose uptake. *Momordica charantia* blocks enzymes like the α-glucosidase and α-amylase which break down complex carbohydrates into absorbable glucose units. This causes delayed absorption of glucose and decreased postprandial blood glucose spikes. This effect is especially advantageous in the management of post-meal hyperglycemia, which is one of the main challenges in diabetes management.[32]

6.5 Regulation of Lipid Metabolism

Besides the impact it has on the glucose metabolism, Momordica charantia has a major effect on the lipid regulation. It has been demonstrated to lower the total cholesterol, triglycerides and low-density lipoprotein (LDL) and raise the high-density lipoprotein (HDL). The mechanisms of these effects are by modulating lipid metabolic pathways, such as increased fatty acid oxidation and decreased lipogenesis. The plant will alleviate the risk of cardiovascular complications, which is often related to diabetes and metabolic syndrome by improving lipid profiles.[33]

6.6 Antioxidant and Anti-inflammatory Actions

One of the causes of insulin resistance and metabolic disorders is chronic oxidative stress and inflammation. Momordica charantia is a good source of flavonoids and phenolic compounds with strong antioxidant activity that can counteract the effects of free radicals and inhibit oxidative stress. Also, it regulates inflammatory processes by decreasing pro-inflammatory cytokines, which enhances insulin signaling and metabolic activity.[34]



Figure 2: Mechanism of glycemic control by Momordica charantia.[35]

7. Role in Metabolic Regulation

Momordica charantia exhibits a broad spectrum of metabolic regulatory effects that extend beyond glycemic control. Its bioactive constituents act on multiple physiological pathways involved in energy balance, lipid metabolism, oxidative stress, and inflammation. These multifactorial actions make it a promising natural agent for managing complex metabolic disorders.[36]

7.1 Anti-obesity Effects

One of the biggest risk factors of insulin resistance and metabolic syndrome is obesity. Momordica charantia has proven itself to be an important anti-obesity agent by regulating lipid metabolism and energy use. It suppresses adipogenesis by suppressing the conversion of preadipocytes into mature fat cells and enhances lipolysis resulting in reduction of fat buildup. Also, AMP-activated protein kinase (AMPK) is activated which increases fatty acid oxidation and decreases lipid storage. There are also studies indicating that it can be used to control appetite and body weight and can be used to bring about overall balance in metabolism.[37]

7.2 Lipid-Lowering Activity

The plant is critical in the enhancement of lipid profiles that are critical in averting cardiovascular issues related to metabolic disorders. The use of Momordica charantia extracts has been proven to lower the serum levels of total cholesterol and triglycerides and raise the levels of high-density lipoprotein (HDL). These are due to the modulation of lipid metabolic routes such as blocking lipogenesis and promoting lipid clearance. This lipid-modulating effect helps to sustain its cardiovascular health.[38]

7.3 Antioxidant and Anti-inflammatory Role

The processes of oxidative stress and persistent inflammation are essential factors in the creation and worsening of metabolic disorders. *Momordica charantia* contains high amounts of phenolic compounds, flavonoids which have excellent antioxidant property, neutralizing reactive oxygen species and guarding against oxidative damage to cellular components. In addition, it has anti-inflammatory effects, which reduce the levels of pro-inflammatory cytokines and mediators. This twofold effect aids in enhancing insulin sensitivity and avoiding metabolic dysfunction.[39]

7.4 Impact on Metabolic Syndrome

Metabolic syndrome is defined as a group of diseases, which include hyperglycemia, dyslipidemia, hypertension, and central obesity. *Momordica charantia* treats several elements of this syndrome by its synergistic effects of hypoglycemic, hypolipidemic, antioxidant, and anti-inflammatory actions. With the focus upon these interconnected pathways, it helps to achieve the general metabolic homeostasis and decrease the risk of the complications related to it, including cardiovascular diseases.[40]

8. Formulation Approaches and Safety

The therapeutic application of *Momordica charantia* has been enhanced through the development of various formulation strategies aimed at improving its stability, bioavailability, and patient compliance. Alongside formulation advancements, evaluation of safety and toxicity is essential to ensure its effective and rational use in metabolic disorders.[41]

8.1 Conventional Formulations: Extracts, Capsules, and Juices

Commercially and traditionally prepared preparations of Momordica charantia contain aqueous and alcoholic extracts, fresh juice, powders, and encapsulated preparations. Fresh fruit juice enjoys a wide application in traditional medicine because of its fast absorption and instant hypoglycemic action. Some of the benefits of standardized extracts and capsules are the ability to have a controlled dosing, stability, and ease of administration. These are widely used dietary supplements that are applied in the management of blood sugar levels and in enhancing metabolism.[42]

8.2 Novel Drug Delivery Systems and Herbal Formulations

Recent studies have been keen on coming up with sophisticated delivery systems in order to counter the drawback of low bioavailability and inconsistency of phytochemical content. Nanoparticle formulations such as nanoemulsions, liposomes, and polymeric nanoparticles have demonstrated the prospect of augmenting the solubility, stability and targeted delivery of bioactive compounds. Besides, polyherbal preparations, which contain Momordica charantia and other active plants have been shown to have synergistic effects resulting to better therapeutic effects in metabolic disorders.[43]

8.3 Toxicity Studies

Momordica charantia has been shown to have a positive safety profile through toxicological assessments. Animal models have been studied in acute and sub-chronic toxicity studies and the plant has not exhibited any adverse effects at therapeutic doses. Nevertheless, when taken in large doses or over an extended period of time, it can cause mild gastrointestinal effects or even hypoglycemia. Potential reproductive toxicity due to excessive doses has also been reported in some studies and the need to have dose control.[44]

8.4 Safety Profile

On the whole, it can be concluded that Momordica charantia is quite safe when consumed in moderation. There is some clinical evidence indicating good tolerability in humans, and few side effects. It should however be used with care in pregnant women, lactating mothers and those receiving conventional antidiabetic medications because of the additive hypoglycemic effects. To be safe and effective, standardization of formulations and appropriate clinical evaluation is necessary.[45]

9. Limitations and Future Perspectives

Although there is a wealth of experimental evidence of the therapeutic potential of Momordica charantia in glycemic and metabolic control, there are a number of constraints to its implementation in mainstream clinical practice. These challenges need to be addressed in order to develop it as an evidence-based and standardized therapeutic agent.[46]

9.1 Lack of Standardization

One of the major limitations is the absence of standardized formulations. The phytochemical composition of *Momordica charantia* varies significantly depending on factors such as geographical origin, plant part used, harvesting conditions, and extraction methods. This variability leads to inconsistencies in therapeutic efficacy. The identification of specific bioactive markers such as charantin and the development of standardized extracts are crucial for ensuring reproducibility and quality control.[47]

9.2 Limited Clinical Trials

Although numerous in vitro and in vivo studies have demonstrated promising antidiabetic effects, well-designed, large-scale clinical trials are still limited. Existing clinical studies often involve small sample sizes, short durations, and variability in study design, which restricts the generalizability of results. More robust randomized controlled trials are needed to validate its safety, efficacy, and long-term benefits in human populations.[48]

9.3 Dose Inconsistency

Another significant challenge is the lack of consensus regarding optimal dosage. Different studies have used varying doses, formulations (juice, extract, powder), and treatment durations, making it difficult to establish standardized dosing guidelines. This inconsistency affects clinical outcomes and may lead to either subtherapeutic effects or potential adverse reactions.[49]

9.4 Need for Molecular and Mechanistic Studies

While several mechanisms of action have been proposed, detailed molecular-level understanding remains incomplete. Advanced studies focusing on gene expression, signaling pathways, proteomics, and metabolomics are required to elucidate its precise mechanisms. Such insights will strengthen its scientific validation and support its integration into modern therapeutic systems.[50]

Future Perspectives

Future research should focus on standardization of extracts, identification of bioactive markers, and development of advanced drug delivery systems to enhance bioavailability. Integration of modern approaches such as systems biology, nanotechnology, and precision medicine can further optimize its therapeutic potential. Additionally, interdisciplinary research combining pharmacology, biotechnology, and clinical sciences will be essential to establish *Momordica charantia* as a reliable and effective agent in metabolic disorder management.[51]

10. CONCLUSION

Momordica charantia has emerged as a potent medicinal plant with significant antidiabetic and metabolic regulatory potential. Extensive experimental evidence supports its ability to effectively reduce blood glucose levels, improve insulin function, and regulate lipid metabolism. The presence of diverse bioactive compounds such as charantin, polypeptide-p, and phenolic constituents contributes to its strong pharmacological profile.

A key advantage of *Momordica charantia* lies in its multi-target mechanism of action. Unlike conventional drugs that often act on a single pathway, this plant exerts its effects through multiple interconnected mechanisms, including enhancement of insulin secretion, improvement of insulin sensitivity, activation of metabolic enzymes, and reduction of oxidative stress and inflammation. This holistic mode of action makes it particularly suitable for managing complex metabolic disorders such as diabetes and metabolic syndrome.

Despite its promising therapeutic benefits, the clinical application of *Momordica charantia* remains limited due to insufficient large-scale clinical validation. Variability in formulations, lack of standardized dosing, and limited long-term safety data are key challenges that need to be addressed.

Overall, *Momordica charantia* represents a promising herbal therapeutic agent with the potential to complement or enhance existing treatment strategies for diabetes and metabolic disorders. Future research focusing on standardization, advanced mechanistic studies, and well-designed clinical trials will be essential to fully establish its role in modern medicine.

ACKNOWLEDGEMENT: Nil.

Conflict of Interest: Nil.

REFERENCES

1. Baynes HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J diabetes metab, May 1, 2015; 6(5): 1-9.
2. Górczyńska-Kosiorz S, Kosiorz M, Dzięgielewska-Gęsiak S. Exploring the interplay of genetics and nutrition in the rising epidemic of obesity and metabolic diseases. Nutrients, Oct. 21, 2024; 16(20): 3562.
3. Tiwari P. Recent trends in therapeutic approaches for diabetes management: a comprehensive update. Journal of diabetes research, 2015; 2015(1): 340838.
4. Gauttam VK, Munjal K, Chopra H, Ahmad A, Rana MK, Kamal MA. A mechanistic review on therapeutic potential of medicinal plants and their pharmacologically active molecules for targeting metabolic syndrome. Current Pharmaceutical Design, Jan. 1, 2024; 30(1): 10-30.
5. Bortolotti M, Biscotti F, Bolognesi A, Polito L. Antiviral Potential of Momordica charantia: From Traditional Use to Modern Implications. Biomedicines, Feb. 11, 2026; 14(2): 412.
6. Peter EL, Mtewa AG, Nagendrappa PB, Kaligirwa A, Sesaazi CD. Systematic review and meta-analysis protocol for efficacy and safety of Momordica charantia L. on animal models of type 2 diabetes mellitus. Systematic Reviews, Jan. 8, 2020; 9(1): 7.
7. Gao Y, Li X, Huang Y, Chen J, Qiu M. Bitter melon and diabetes mellitus. Food Reviews International, Jan. 2, 2023; 39(1): 618-38.
8. Henderson VC, Kimmelman J, Fergusson D, Grimshaw JM, Hackam DG. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS medicine, Jul. 23, 2013; 10(7): e1001489.
9. Khorsan R, Crawford C. External validity and model validity: A conceptual approach for systematic review methodology. Evidence-Based Complementary and Alternative Medicine, 2014; 2014(1): 694804.
10. Asna AC, Joseph J, Joseph John K. Botanical description of bitter gourd. InThe bitter gourd genome, Jan. 30, 2020; 7-31. Cham: Springer International Publishing.
11. Bharathi LK, John KJ. Momordica genus in Asia-An overview. New Delhi: Springer, 2013 Mar 21.
12. Kumar KS, Bhowmik D. Traditional medicinal uses and therapeutic benefits of Momordica charantia Linn. International Journal of Pharmaceutical Sciences Review and Research, 2010; 4(3): 23-8.
13. Giuliani C, Tani C, Maleci Bini L. Micromorphology and anatomy of fruits and seeds of bitter melon (Momordica charantia L., Cucurbitaceae). Acta Societatis Botanicorum Poloniae, 2016; 85(1).
14. Beloin N, Gbeassor M, Akpagana K, Hudson J, de Soussa K, Koumaglo K, Arnason JT. Ethnomedicinal uses of Momordica charantia (Cucurbitaceae) in Togo and relation to its phytochemistry and biological activity. Journal of Ethnopharmacology, Jan. 4, 2005; 96(1-2): 49-55.
15. Li Z, Xia A, Li S, Yang G, Jin W, Zhang M, Wang S. The pharmacological properties and therapeutic use of bitter melon (Momordica charantia L.). Current Pharmacology Reports, Jun. 2020; 6(3): 103-9.
16. Daniel P, Supe U, Roymon MG. A review on phytochemical analysis of Momordica charantia. Int J Adv Pharm Biol Chem., Jan. 2014; 3(1): 214-20.
17. Oyelere SF, Ajayi OH, Ayoade TE, Pereira GB, Owoyemi BC, Ilesanmi AO, Akinyemi OA. A detailed review on the phytochemical profiles and anti-diabetic mechanisms of Momordica charantia. Heliyon, Apr. 1, 2022; 8(4).
18. Guarniz WA, Canuto KM, Ribeiro PR, Dodou H, Magalhaes K, Sa K, do Nascimento PG, Silva KL, Sales GW, Monteiro MP, Nogueira NA. Momordica

charantia L. Variety from northeastern Brazil: analysis of antimicrobial activity and phytochemical components. Pharmacognosy Journal, Nov. 2019; 11(6): 366-70.
19. Zahan S, Uddin SN, Hossain MK, Mannan AB, Rahman M, Chen U, Mazumder T, Uddin AM, Arefin S, Hussain MS. Evaluation of phytochemical and pharmacological properties of seeds of Momordica charantia. Avicenna Journal of Phytomedicine, Sep. 2020; 10(5): 448.
20. Elekofehinti OO, Ariyo EO, Akinjiyan MO, Olayeriju OS, Lawal AO, Adanlawo IG, Rocha JB. Potential use of bitter melon (Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies. Pathophysiology, Dec. 1, 2018; 25(4): 327-33.
21. Xu B, Li Z, Zeng T, Zhan J, Wang S, Ho CT, Li S. Bioactives of Momordica charantia as potential anti-diabetic/hypoglycemic agents. Molecules, Mar. 28, 2022; 27(7): 2175.
22. Poovitha S, Parani M. In vitro and in vivo α-amylase and α-glucosidase inhibiting activities of the protein extracts from two varieties of bitter gourd (Momordica charantia L.). BMC complementary and alternative medicine, Jul. 18, 2016; 16(1): 185.
23. Matheka DM, Kiama TN, Alkizim FO, Bukachi F. Glucose-lowering effects of Momordica charantia in healthy rats. African Journal of Diabetes Medicine, Nov. 1, 2011; 19(2).
24. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. The American journal of medicine, Apr. 17, 2000; 108(6): 9-14.
25. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. British Journal of Nutrition, Dec. 2009; 102(12): 1703-8.
26. Cho JH, Chang SA, Kwon HS, Choi YH, Ko SH, Moon SD, Yoo SJ, Song KH, Son HS, Kim HS, Lee WC. Long-term effect of the Internet-based glucose monitoring system on HbA1c reduction and glucose stability: a 30-month follow-up study for diabetes management with a ubiquitous medical care system. Diabetes care, Dec. 1, 2006; 29(12): 2625-31.
27. Banerjee J, Chanda R, Samadder A. Anti-diabetic activity of Momordica charantia or bitter melon: a review. Acta Scientific Pharmaceutical Sciences, 2019; 3: 24-30.
28. Garau C, Cummings E, Phoenix DA, Singh J. Beneficial effect and mechanism of action of Momordica charantia in the treatment of diabetes mellitus: a mini review. International Journal of Diabetes and Metabolism, Mar. 2003; 11(3): 46-55.
29. Vesa CM, Bungau SG, Tit DM, Purza AL, Bungau AF, Radu AF, Stoicescu M. Exploring the impact of Momordica charantia on diabetes mellitus: from cell cultures to clinical studies. Pharmacophore, 2024; 15(2-2024): 32-42.
30. Sridhar MG, Vinayagamoorthi R, Suyambunathan VA, Bobby Z, Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. British Journal of Nutrition, Apr. 2008; 99(4): 806-12.
31. Kaur M, Deep G, Jain AK, Raina K, Agarwal C, Wempe MF, Agarwal R. Bitter melon juice activates cellular energy sensor AMP-activated protein kinase causing apoptotic death of human pancreatic carcinoma cells. Carcinogenesis, Jul. 1, 2013; 34(7): 1585-92.
32. Liu J, Lei Y, Guo M, Wang L. Research Progress on the Hypoglycemic Effects and Mechanisms of Action of Momordica charantia polysaccharide. Journal of Food Biochemistry, 2023; 2023(1): 8867155.
33. Phimarn W, Sungthong B, Saramunee K, Caichompoo W. Efficacy of Momordica charantia L. on blood glucose, blood lipid, and body weight: A meta-analysis of randomized controlled trials. Pharmacognosy Magazine, Jul. 1, 2018; 14(56): 351-8.
34. Yang SJ, Choi JM, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Park CY. Preventive effects of bitter melon (Momordica charantia) against insulin resistance and diabetes are associated with the inhibition of NF-κB and JNK pathways in high-fat-fed OLETF rats. The Journal of Nutritional Biochemistry, Mar. 1, 2015; 26(3): 234-40.
35. Pahlavani N, Roudi F, Zakerian M, Ferns GA, Navashenaq JG, Mashkouri A, Ghayour-Mobarhan M, Rahimi H. Possible molecular mechanisms of glucose-lowering activities of Momordica charantia (karela) in diabetes. Journal of cellular biochemistry, Jul. 2019; 120(7): 10921-9.
36. Cortez-Navarrete M, Méndez-del Villar M, Ramos-González EJ, Pérez-Rubio KG. Momordica charantia: A review of its effects on metabolic diseases and mechanisms of action. Journal of medicinal food, Oct. 2021; 24(10): 1017-27.
37. Fan M, Kim EK, Choi YJ, Tang Y, Moon SH. The role of Momordica charantia in resisting obesity. International Journal of Environmental Research and Public Health, Sep. 2019; 16(18): 3251.
38. Wazir M, Olanrewaju OA, Yahya M, Kumari J, Kumar N, Singh J, Al-Itbi AY, Kumari K, Ahmed A, Islam T, Varrassi G. Lipid disorders and cardiovascular risk: a comprehensive analysis of current perspectives. Cureus, Dec. 31, 2023; 15(12).
39. Richter E, Geetha T, Burnett D, Broderick TL, Babu JR. The effects of Momordica charantia on type 2 diabetes mellitus and Alzheimer's disease. International journal of molecular sciences, Feb. 28, 2023; 24(5): 4643.
40. Ahmed M, Kumari N, Mirgani Z, Saeed A, Ramadan A, Ahmed MH, Almobarak AO. Metabolic syndrome; Definition, Pathogenesis, Elements, and the Effects of medicinal plants on it's

elements. Journal of Diabetes & Metabolic Disorders, Jun. 2022; 21(1): 1011-22.
41. Thent ZC, Das S, Zaidun NH. Emerging trends on drug delivery strategy of Momordica charantia against diabetes and its complications. Current Drug Delivery, May 1, 2018; 15(4): 453-60.
42. Prabhakar PK, Doble M. Mechanism of action of natural products used in the treatment of diabetes mellitus. Chinese journal of integrative medicine, Aug. 2011; 17(8): 563-74.
43. Zuccari G, Alfei S. Development of phytochemical delivery systems by nano-suspension and nano-emulsion techniques. International Journal of Molecular Sciences, Jun. 6, 2023; 24(12): 9824.
44. Abdillah S, Inayah B, Febrianti AB, Nafisa S. Acute and Subchronic Toxicity of Momordica Charantia L Fruits Ethanolic Extract in Liver and Kidney. Systematic Reviews in Pharmacy, Dec. 1, 2020; 11(12).
45. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. American Journal of Health-System Pharmacy, Feb. 15, 2003; 60(4): 356-9.
46. Chaturvedi P. Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects. Journal of medicinal food, Feb. 2012; 15(2): 101-7.
47. Bara LV, Budau R, Apahidean AI, Bara CM, Iancu CV, Jude ET, Cheregi GR, Timar AV, Bei MF, Osvat IM, Domocos D. Momordica charantia L.: Functional Health Benefits and Uses in the Food Industry. Plants, Aug. 25, 2025; 14(17): 2642.
48. Thakur S, Daley B, Klubo-Gwiezdzinska J. The role of an anti-diabetic drug metformin in the treatment of endocrine tumors. Journal of molecular endocrinology, Aug. 1, 2019; 63(2): R17-35.
49. Puri V, Nagpal M, Singh I, Singh M, Dhingra GA, Huanbutta K, Dheer D, Sharma A, Sangnim T. A comprehensive review on nutraceuticals: therapy support and formulation challenges. Nutrients, Nov. 3, 2022; 14(21): 4637.
50. van Mil MH, Boerwinkel DJ, Waarlo AJ. Modelling molecular mechanisms: A framework of scientific reasoning to construct molecular-level explanations for cellular behaviour. Science & Education, Jan. 2013; 22(1): 93-118.
51. Zhang A, Sun H, Wang P, Han Y, Wang X. Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach. Complementary therapies in medicine, Feb. 1, 2012; 20(1-2): 93-9.